FDA's Advisory Cmte. Meeting On Bladder Pain Syndrome May Signal Policy Changes

 
• By Derrick Gingery

The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.

FDA entrance sign 2016
The advisory committee meeting could lead to policy changes in painful bladder syndrome.

More from US FDA Performance Tracker

More from Regulatory Trackers